Biotechnology
Company Overview of BioArctic Neuroscience AB
Company Overview
BioArctic Neuroscience AB develops immunotherapeutic treatments for neurodegenerative diseases. It provides BAN2401, a technology platform that is used to isolate various proteins implicated in CNS disorders and study their aggregation properties, prepare and stabilize protofibrils, and develop protofibril specific monoclonal antibodies. The company offers treatments for people suffering from Alzheimer’s, Parkinson’s, ALS, Huntington’s, and Creutzfeldt-Jacob’s diseases. BioArctic Neuroscience AB was founded in 2003 and is based in Stockholm, Sweden.
Warfvinges väg 39
Stockholm, 112 51
Sweden
Founded in 2003
Key Executives for BioArctic Neuroscience AB
Similar Private Companies By Industry
| Company Name | Region |
| Octapharma Nordic AB | Europe |
| Cantargia AB | Europe |
| Ellem Läkemedel AB | Europe |
| Karocell Tissue Engineering AB | Europe |
| NemerPharma | Europe |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Citizens Budget Commission | United States |
Post a JobJobs
- Adelphi, MD | University of Maryland University CollegePosted: May 07
- New York, NY | Robert W. BairdPosted: Apr 21
- Kennebunk, ME | CorningPosted: May 24
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
Sponsored Financial Commentaries
Sponsored Links
To contact BioArctic Neuroscience AB, please visit www.bioarctic.se. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
